Pfizer forces UK Takeover Panel to plan rule changes
This article was originally published in Scrip
Executive Summary
The UK Takeover Panel, which came into the pharma limelight during the unfolding saga of Pfizer's pursuit of AstraZeneca earlier this year, is proposing amendments to its Takeover Code. In brief, it now wants to differentiate clearly between firm undertakings made by offerors and less binding statements of intentions, and clarify its own ability to enforce compliance with those undertakings.